A Dose Escalation Study of R115777 (Zarnestra) Combined With Velcade (PS-341) in Patients With Relapsed Multiple Myeloma
Phase of Trial: Phase I/II
Latest Information Update: 07 Oct 2013
At a glance
- Drugs Tipifarnib (Primary) ; Bortezomib
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 07 Oct 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 26 Mar 2009 Additional lead trial centres and lead investigator identified as reported by ClinicalTrials.gov.